Dr. Ann Partridge is the North American PI for the Pregnancy Outcome And Safety Of Interrupting Therapy For Women With Endocrine Responsive BC (POSITIVE) study (IBCSG 48-14 / BIG 8-13/ ALLIANCE A221405), and hopes that you will be willing to share the attached brochure with interested patients and clinicians.

POSTIVE is an international clinical study evaluating whether it is safe for women to interrupt their endocrine therapy to attempt pregnancy after breast cancer. Specifically, the study hopes to determine whether endocrine therapy can be paused for up to two years to allow for conception without increasing the risk of breast cancer recurrence. The study will enroll up to 500 women with hormone-sensitive breast cancer to answer this important question.

If you would like to learn more about this study, please click here. Please do not hesitate to contact us if you would like us to identify other sites participating as this is an international research effort coordinated by International Breast Cancer Study Group worldwide and ALLIANCE for Clinical Trials in Oncology in North America under the umbrella of the Breast International Group.